Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 37.9% during trading on Friday . The company traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares were traded during mid-day trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The business has a 50-day moving average of C$0.09 and a 200 day moving average of C$0.07. The company has a market capitalization of C$17.42 million, a PE ratio of -10.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Stock Splits, Do They Really Impact Investors?
- Walgreens Stock Poised for a Rebound: Why Analysts Are Bullish
- Stock Market Sectors: What Are They and How Many Are There?
- Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns
- How to Buy Cheap Stocks Step by Step
- Is Domino’s Recent Dip a Recipe for Long-Term Gains?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
